Show simple item record

dc.contributor.authorPerrotti, Danilo
dc.contributor.authorAgarwal, Anupriya
dc.contributor.authorLucas, Claire
dc.contributor.authorNarla, Goutham
dc.contributor.authorNeviani, Paolo
dc.contributor.authorOdero, Maria D.
dc.contributor.authorRuvolo, Peter P.
dc.contributor.authorVerrills, Nicole M.
dc.date.accessioned2019-08-01T00:44:15Z
dc.date.available2019-08-01T00:44:15Z
dc.date.issued2019-07-17
dc.identifier.citationPerrotti, D., Agarwal, A., Lucas, C., Narla, G., Neviani, P., Odero, M., . . . Verrills, N. (2019). Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia". Science Translational Medicine, 11(501) doi:10.1126/scitranslmed.aau0416
dc.identifier.issn1946-6234
dc.identifier.doi10.1126/scitranslmed.aau0416
dc.identifier.urihttp://hdl.handle.net/10034/622468
dc.description.abstractLB100 does not sensitize CML stem cells to tyrosine kinase inhibitor–induced apoptosis.
dc.publisherAmerican Association for the Advancement of Science
dc.relation.urlhttps://stm.sciencemag.org/content/11/501/eaau0416?rss=1&intcmp=trendmd-stm
dc.titleComment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
dc.typearticle
dc.identifier.eissn1946-6242
dc.identifier.journalScience Translational Medicine
dc.date.updated2019-08-01T00:44:15Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1126/scitranslmed.aau0416
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.licenseref.startdate2219-07-17
rioxxterms.publicationdate2019-07-17
dc.terms.dateAccepted2019-05-09


Files in this item

Thumbnail
Name:
Comment article.pdf
Embargo:
2219-07-17
Size:
1.202Mb
Format:
PDF
Request:
Main article

This item appears in the following Collection(s)

Show simple item record